WALTHAM, Mass., April 29, 2015 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that William Heiden, AMAG’s chief executive officer, and Frank Thomas, AMAG’s president and chief operating officer, will participate in two upcoming investor conferences. The sessions will include a discussion on the company’s financial results, business update, and growth prospects.
The sessions will take place as follows:
May 6, at 8:40 a.m. ET – Deutsche Bank 40th Annual Healthcare Conference in Boston; and
May 7, at 12:40 p.m. ET – Baird 2015 Growth Stock Conference in Chicago.
A live audio webcast of the discussions will be accessible through the Investors section of the company’s website at www.amagpharma.com. Following the conference, the webcast will be archived on the AMAG Pharmaceuticals, Inc. website for 30 days.
AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company with a focus on maternal health, anemia and cancer supportive care. The primary goal of AMAG is to bring to market therapies that provide clear benefits and improve patients’ lives. In addition to continuing to pursue opportunities to make new advancements in patients’ health and to enhance treatment accessibility, AMAG intends to continue to expand and diversify its portfolio through the in-license or purchase of additional pharmaceutical products or companies. For additional company information, please visit www.amagpharma.com.
CONTACT: Linda Lennox
Vice President, Investor Relations & Corporate Communications
AMAG Pharmaceuticals, Inc.